Mr. Lehoux, I think Mr. Roy did a good job of summarizing what we wanted to tell the committee about approvals.
We should do the same thing with vaccine development as we did during the COVID‑19 pandemic. We established an expedited approvals procedure for products that were recognized elsewhere in the world. We usually don't have that procedure here in Canada. There's no expedited procedure when the product is used in the United States or Europe, for example. We have to follow the usual procedures in Canada.
Canada is a small pork producer. Consequently, companies don't want to invest the millions of dollars necessary to sell their product.